Abstract:Backgroud: The co-administration of Chinese patent medicine with calcium channel blockers (CCBs) is a prevalent practice in China for treating essential hypertension (EH). However, robust evidence supporting the efficacy and safety of tailored combinations of different Chinese patent medicines with CCBs, according to individual patient conditions, is still limited. This study sought to elucidate the efficacy and safety of these combinations using a systematic review and network meta-analysis. Materials and methods: Relevant studies were sourced from established databases, incorporating randomized controlled trials published up to 1 February 2023. The ROB2 tool from the Cochrane Collaborative Network was employed to independently assess and cross-verify the quality of the included literature. A network meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) 2020 and PRISMA-Network Meta-Analyses (PRISMA-NMA) guidelines. A Bayesian network meta-analysis was utilized to gauge the efficacy and safety of distinct integrations of Chinese patent medicine and CCBs. Primary outcomes were interpreted using a paired fixed-effect meta-analysis. Publication bias was appraised through Egger's test and represented with funnel plots. All statistical analyses were executed within the R statistical framework. Results: Following rigorous selection, data extraction, and bias evaluation, 36 articles were incorporated. Tianma Gouteng Granule, when combined with CCBs, displayed superior efficacy in reducing systolic blood pressure (SBP). In terms of diastolic blood pressure (DBP) reduction, Songling Xuemaikang Capsule combined with CCBs emerged as the most effective. Regarding enhancement of antihypertensive effective rates, Qinggan Jiangya Capsule paired with CCBs demonstrated optimal results. For diminishing Traditional Chinese Medicine syndrome scores, the Qiangli Dingxuan Tablet and CCBs combination proved most beneficial. When aiming to reduce total cholesterol (TC), triglycerides (TG), and low-density lipoprotein cholesterol (LDL-C) levels, Tianma Gouteng Granule and CCBs showcased superior results. In contrast, the combination of Songling Xuemaikang Capsule and CCBs was more effective in reducing LDL-C, tumor necrosis factor-alpha (TNF-α), and interleukin-6 (IL-6). Conclusion: This study underscores variability in outcomes from combining Chinese patent medicine and CCBs for hypertension, emphasizing the importance of personalized medicinal combinations, especially Tianma Gouteng Granule and Songling Xuemaikang Capsule. The results offer robust evidence to inform clinical guidelines for essential hypertention and significantly aid clinician in seleting appropriate Chinese patent medicines for treatment.

A18728 Combination of Amlodipine with Diuretics or Telmisartan in High-risk Hypertensive Patients

[A Randomized, Double-Blind, Double-Dummy Study Comparing a Fixed Dose Combination of Telmisartan 80 Mg Plus Hydrochlorothiazide 12.5 Mg to Telmisartan 80 Mg in Chinese Hypertensive Patients Who Failed to Respond Adequately to Telmisartan 80 Mg].

Efficacy and Safety of the Compound of Candesartan Cilexetial and Hydrochlorothiazide in Patients with Essential Hypertension

Aliskiren Therapy in Hypertension and Cardiovascular Disease: a Systematic Review and a Meta-Analysis

Synergistic effect of amlodipine and atorvastatin on blood pressure, left ventricular remodeling, and C-reactive protein in hypertensive patients with primary hypercholesterolemia

Comparison of two single-pill dual combination antihypertensive therapies in Chinese patients: a randomized, controlled trial

G-002 AMLODIPINE/VALSARTAN 5/160 MG VERSUS VALSARTAN 160 MG IN PREDOMINANTLY CHINESE PATIENTS WITH STAGE 1 OR 2 ESSENTIAL HYPERTENSION NOT ADEQUATELY CONTROLLED ON VALSARTAN 160 MG MONOTHERAPY

Phase III randomized clinical trial of efficacy and safety of amlodipine and candesartan cilexetil combination for hypertension treatment

Effect of combining valsartan and amlodipine in the treatment of type 2 diabetes mellitus complicated by hypertension

Efficacy and safety of a single-pill versus free combination of perindopril/indapamide/amlodipine: a multicenter, randomized, double-blind study in Chinese patients with hypertension

Amlodipine/valsartan 5/160mg Versus Valsartan 160mg in Chinese Hypertensives

Telmisartan and Hydrochlorothiazide Antihypertensive Treatment in High Sodium Intake Population: a Randomized Double-Blind Trial

Efficacy and Safety of Olmesartan Medoxomil-Amlodipine Besylate Tablet in Chinese Patients with Essential Hypertension: A Prospective, Single-Arm, Multi-Center, Real-World Study

Chinese patent medicine combined with calcium channel blockers in the treatment of essential hypertension:a Bayes network meta-analysis and systematic review

A clinical trial for evaluating efficacy and safety of amlodipine besylate/atorvastatin calcium in treating hypertension complicated with hyperlipidemia

578 Single-pill Combination of Telmisartan 80 Mg/amlodipine 5 Mg Provides Superior Blood Pressure Reductions to Amlodipine 5 Mg in Hypertensive Patients Whowere Uncontrolled on Amlodipine 5 Mg Monotherapy

Efficacy and Safety of Valsartan/Amlodipine Single-Pill Combination in 11,422 Chinese Patients with Hypertension: an Observational Study

China STudy of Valsartan/amlodipine Fixed-Dose Combination-Based Long-Term Blood Pressure Management in HypertenSive Patients: a One-Year Registry (china STATUS III)

Efficacy and Safety of Fixed Combination of Nitrendipine and Atenolol in Treatment for Patients with Mild to Moderate Essential Hypertension and Their Optimal Dosage Matching

Efficacy and safety of Qiangli Dingxuan tablet combined with amlodipine besylate for essential hypertension: a randomized, double-blind, placebo-controlled, parallel-group, multicenter trial

Efficacy and Safety of Fixed-Dose Perindopril Arginine/Amlodipine in Hypertensive Patients Not Adequately Controlled with Amlodipine 5 Mg or Perindopril Tert-Butylamine 4 Mg Monotherapy